Bluejay Diagnostics Reports $7.38 Million in Cash and Advances Clinical Milestones
Bluejay Diagnostics reported $7.38M in cash as of Q3 2026, up from $5.16M at year-end 2025. The company completed SYMON-II study enrollment and advanced Symphony platform manufacturing. It aims for FDA 510(k) submission in H1 2027, contingent on validation. Current funds should last until Q2 2027, with additional financing needed for long-term plans.
How this was made

The 30-second read
Why it matters
The disclosed cash runway to Q2 2027 and need for additional financing suggest short‑term downside risk, while trial progress could be a catalyst if FDA clearance is achieved.
Market read
Micro‑cap news with modest immediate market relevance; investors will watch for financing updates and FDA filing outcomes.
What to watch
Potential government contract via Lovell Government Services and manufacturing partnership with Sanyoseiko may improve future cash flow.
Background
Bluejay Diagnostics is a micro‑cap biotech developing an IL‑6 sepsis test. The filing reports cash levels and trial enrollment milestones.
Ticker impact
Bluejay Diagnostics disclosed $7.38M cash and completed SYMON-II enrollment, indicating runway to Q2 2027 and upcoming FDA 510(k) filing.
likely pressure as investors weigh cash constraints and need for additional financing
Micro‑cap with modest cash runway; no new financing announced, so market may discount the stock until funding is secured.
Market effects
Provides a data point on early‑stage sepsis diagnostics market but unlikely to shift sector sentiment.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact given the company's size and niche focus.
Counterpoint
If the company secures a strategic partnership or financing soon, the cash runway could be less of a concern.
Key entities
- companyBluejay Diagnostics, Inc.
Developer of the Symphony IL‑6 sepsis diagnostic platform.
- partnerToray Industries
Contractual partner for cartridge manufacturing deadline.
